Best Case
15%Broad coverage and competitive pricing make the approved formulation the default bevacizumab option.
Forecast dossier
Wet AMD treatment will split into on-label ophthalmic bevacizumab and price-driven compounded use
United States approval of LYTENAVA created the first approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration. Retina practices now have a standardized labeled option, but lower-cost compounded bevacizumab will remain competitive unless reimbursement narrows the price difference.
Verdict: Approval changes the legal and quality-assurance landscape, but reimbursement will determine whether it changes prescribing at scale.
Date
Jul 24, 2026
Reliability
79
Harm potential
Medium
Scenario odds
Baseline
50%Practices use the approved product selectively while compounded bevacizumab retains price-sensitive patients.
Adverse Case
25%Coverage restrictions and price differences produce limited adoption.
Wildcard
10%A safety, supply or reimbursement event rapidly shifts prescribing toward or away from the product.
Timeline projections
1-Year
Coverage determines launch
Developments: Payers establish policies and retina practices test the product in selected patients.
Risks: Unfavorable reimbursement suppresses ordering.
Outlook: Adoption is measurable but uneven.
2-Year
Market segmentation stabilizes
Developments: Practices distinguish patients by coverage, cost sensitivity and clinical preference.
Risks: Competing drugs may improve dosing convenience.
Outlook: Approved and compounded bevacizumab coexist.
3-Year
Real-world evidence gains influence
Developments: Safety, adherence and switching data shape guidelines and payer policy.
Risks: Evidence may show little practical advantage over compounding.
Outlook: Market share follows demonstrated value rather than labeling alone.
5-Year
Standardized ophthalmic biologics expand
Developments: Other repurposed biologics pursue eye-specific formulations and approvals.
Risks: Development costs may exceed achievable pricing.
Outlook: The approval provides a regulatory precedent beyond one medicine.
10-Year
Retinal therapy becomes more personalized
Developments: Longer-duration and biomarker-guided therapies reduce reliance on frequent bevacizumab injections.
Risks: Current products lose relevance faster than expected.
Outlook: Bevacizumab remains a cost benchmark even if its share declines.
20-Year
Compounding role narrows but persists
Developments: Manufactured ophthalmic formulations cover more commonly compounded biologics.
Risks: Access gaps preserve demand for low-cost alternatives.
Outlook: Compounding focuses on unmet formulations and affordability.
50-Year
Approval model becomes historical precedent
Developments: Regulators routinely evaluate purpose-built versions of widely used off-label biologics.
Risks: New treatment modalities make injectable anti-VEGF therapy obsolete.
Outlook: The durable effect is a pathway for converting established off-label practice into standardized products.
Planning prompts to verify
- Track payer formularies and physician-administered drug reimbursement decisions.
- Compare net treatment costs with compounded bevacizumab and competing anti-VEGF drugs.
- Monitor quarterly prescription volume and postmarket safety reports.